INVIVYD, INC. Increase (Decrease) in Accounts Receivable
INVIVYD, INC. (IVVD) reported Increase (Decrease) in Accounts Receivable of -$2.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- INVIVYD, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$476.00K, a 287.40% decline year-over-year.
- INVIVYD, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$2.22M.
- INVIVYD, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $4.07M, a 47.82% increase year-over-year.
- INVIVYD, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $1.36M, a 74.17% decline year-over-year.
- INVIVYD, INC. increase (decrease) in accounts receivable for fiscal 2025 was $3.34M, a 69.40% decline from fiscal 2024.
- INVIVYD, INC. increase (decrease) in accounts receivable for fiscal 2024 was $10.91M.
- INVIVYD, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.70M 10-Q · filed 2026-08-13 | $1.37M derived: sum of 3 quarters · filed 2026-08-13 | $2.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.22M 10-Q · filed 2026-05-14 | $1.85M derived: sum of 2 quarters · filed 2026-05-14 | $3.21M derived: sum of 3 quarters · filed 2026-05-14 | $3.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.43M derived: sum of 2 quarters · filed 2026-03-05 | $5.68M derived: sum of 3 quarters · filed 2026-08-13 | $3.34M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.61M derived: sum of 2 quarters · filed 2026-08-13 | -$731.00K 10-Q · filed 2025-11-06 | $2.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.09M 10-Q · filed 2026-08-13 | $661.00K derived: sum of 3 quarters · filed 2026-08-13 | $5.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.35M 10-Q · filed 2026-05-14 | $407.00K derived: sum of 2 quarters · filed 2026-05-14 | $5.67M derived: sum of 3 quarters · filed 2026-05-14 | $8.56M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $8.02M derived: sum of 2 quarters · filed 2026-03-05 | $10.91M derived: sum of 3 quarters · filed 2026-03-05 | $10.91M 10-K · filed 2026-03-05 |
| 2024-09-30 | $5.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.15M derived: sum of 2 quarters · filed 2025-11-06 | $8.15M 10-Q · filed 2025-11-06 | $8.15M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.89M 10-Q · filed 2025-08-14 | $2.89M derived: sum of 3 quarters · filed 2025-08-14 | $2.89M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-05-15 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |